Hemodialysis Care: Evolving to Enhance Patient-Level Outcomes

Hemodialysis remains the predominant form of kidney replacement therapy worldwide, yet mortality, hospitalization, symptom burden, and impaired health-related quality of life remain substantial. Historically, dialysis innovation has emphasized surrogate measures such as solute clearance and biochemical targets. Although these advances have improved treatment delivery, gains in patient-important outcomes-including survival, hospitalization, symptoms, and functional status-have been limited, suggesting diminishing returns from further optimization of traditional adequacy targets. Dialysis therapies should therefore be evaluated by their effects on clinical outcomes, patient-reported outcomes, safety, equity, sustainability, and value. This review assesses contemporary extracorporeal modalities and emerging technologies using an outcome-based framework incorporating implementation, health-system implications, and patient priorities. High-flux hemodialysis is the current standard of care but has not consistently been associated with lower all-cause mortality despite achievement of modern adequacy targets. Medium cut-off membranes, adsorption-based approaches, personalized schedules, and portable, wearable, or implantable technologies offer compelling physiologic rationales and may improve selected surrogate measures; however, evidence of meaningful clinical benefit remains limited. Among extracorporeal therapies, online hemodiafiltration has the strongest evidence base. Randomized trials and individual-participant-data meta-analyses indicate better survival with high-volume online hemodiafiltration versus high-flux hemodialysis, with supportive patient-reported and cost-effectiveness evidence. However, CONVINCE patients achieved high convection volumes; benefit is uncertain for those unable to reach these targets, and implementation depends on infrastructure, reimbursement, regulation, and quality assurance. Current evidence supports shifting dialysis innovation from surrogate endpoints toward outcomes that matter to patients. Physiologic plausibility and surrogate improvements alone should not justify widespread adoption. Future progress requires rigorous comparative-effectiveness research, implementation science, real-world evidence, routine integration of standardized patient-reported outcomes, and attention to environmental sustainability and equitable access. Aligning reimbursement, quality metrics, implementation, and policy with patient-level outcomes will be essential to translate technological advances into better care for people with kidney failure.